{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:20:55Z","timestamp":1707524455947},"reference-count":14,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,1,17]]},"DOI":"10.7759\/cureus.21346","type":"journal-article","created":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T04:42:21Z","timestamp":1642480941000},"source":"Crossref","is-referenced-by-count":0,"title":["Voriconazole-Induced Cholestatic Hepatotoxicity in an Immune Competent Patient"],"prefix":"10.7759","author":[{"given":"Yaser","family":"Mohammed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Abousamra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed Atef I","family":"Abdeldayem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mansoor","family":"Zafar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tila","family":"Muhammad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.12834","article-title":"Adverse effects of voriconazole: over a decade of use","volume":"30","author":"Levine MT","year":"2016","unstructured":"Levine MT, Chandrasekar PH. Adverse effects of voriconazole: over a decade of use. Clin Transplant. 2016, 30:1377-86. 10.1111\/ctr.12834","journal-title":"Clin Transplant"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1086\/374248","article-title":"Safety of voriconazole and dose individualization","volume":"36","author":"Lutsar I","year":"2003","unstructured":"Lutsar I, Hodges MR, Tomaszewski K, Troke PF, Wood ND. Safety of voriconazole and dose individualization. Clin Infect Dis. 2003, 36:1087-8. 10.1086\/374248","journal-title":"Clin Infect Dis"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1400","article-title":"CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementation of pharmacogenomics?","volume":"34","author":"Owusu Obeng A","year":"2014","unstructured":"Owusu Obeng A, Egelund EF, Alsultan A, Peloquin CA, Johnson JA. CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementation of pharmacogenomics?. Pharmacotherapy. 2014, 34:703-18. 10.1002\/phar.1400","journal-title":"Pharmacotherapy"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1517\/14740330903485637","article-title":"Voriconazole therapeutic drug monitoring: focus on safety","volume":"9","author":"Pasqualotto AC","year":"2010","unstructured":"Pasqualotto AC, Xavier MO, Andreolla HF, Linden R. Voriconazole therapeutic drug monitoring: focus on safety. Expert Opin Drug Saf. 2010, 9:125-37. 10.1517\/14740330903485637","journal-title":"Expert Opin Drug Saf"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2515\/therapie\/2011009","article-title":"[Level of evidence for therapeutic drug monitoring of voriconazole]","volume":"66","author":"Hulin A","year":"2011","unstructured":"Hulin A, Dailly E, Le Guellec C. [Level of evidence for therapeutic drug monitoring of voriconazole]. Therapie. 2011, 66:109-14. 10.2515\/therapie\/2011009","journal-title":"Therapie"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s12281-020-00371-w","article-title":"Applying pharmacogenomics to antifungal selection and dosing: are we there yet?","volume":"14","author":"Miller MA","year":"2020","unstructured":"Miller MA, Lee YM. Applying pharmacogenomics to antifungal selection and dosing: are we there yet?. Curr Fungal Infect Rep. 2020, 14:63-75. 10.1007\/s12281-020-00371-w","journal-title":"Curr Fungal Infect Rep"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.14309\/crj.0000000000000010","article-title":"Voriconazole-induced hepatotoxicity presenting with severe hepatic encephalopathy after liver transplantation","volume":"6","author":"Tasleem SH","year":"2019","unstructured":"Tasleem SH, Cappell MS. Voriconazole-induced hepatotoxicity presenting with severe hepatic encephalopathy after liver transplantation. ACG Case Rep J. 2019, 6:1-4. 10.14309\/crj.0000000000000010","journal-title":"ACG Case Rep J"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2012.09.011","article-title":"Voriconazole hepatotoxicity in severe liver dysfunction","volume":"66","author":"Sol\u00eds-Mu\u00f1oz P","year":"2013","unstructured":"Sol\u00eds-Mu\u00f1oz P, L\u00f3pez JC, Bernal W, et al.. Voriconazole hepatotoxicity in severe liver dysfunction. J Infect. 2013, 66:80-6. 10.1016\/j.jinf.2012.09.011","journal-title":"J Infect"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1086\/525258.V","article-title":"Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America","volume":"46","author":"Walsh TJ","year":"2008","unstructured":"Walsh TJ, Anaissie EJ, Denning DW, et al.. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008, 46:327-60. 10.1086\/525258.V","journal-title":"Clin Infect Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu017","article-title":"Voriconazole metabolism, toxicity, and the effect of cytochrome P450 2C19 genotype","volume":"209","author":"Zonios D","year":"2014","unstructured":"Zonios D, Yamazaki H, Murayama N, et al.. Voriconazole metabolism, toxicity, and the effect of cytochrome P450 2C19 genotype. J Infect Dis. 2014, 209:1941-8. 10.1093\/infdis\/jiu017","journal-title":"J Infect Dis"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S12714","article-title":"Update on the optimal use of voriconazole for invasive fungal infections","volume":"4","author":"Lat A","year":"2011","unstructured":"Lat A, Thompson GR 3rd. Update on the optimal use of voriconazole for invasive fungal infections. Infect Drug Resist. 2011, 4:43-53. 10.2147\/IDR.S12714","journal-title":"Infect Drug Resist"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1086\/367933","article-title":"Voriconazole: a new triazole antifungal agent","volume":"36","author":"Johnson LB","year":"2003","unstructured":"Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis. 2003, 36:630-7. 10.1086\/367933","journal-title":"Clin Infect Dis"},{"key":"ref13","unstructured":"Voriconazole. (2022). https.\/\/bnf.nice.org.uk\/drug\/voriconazole.html."},{"key":"ref14","unstructured":"Voriconazole Levels. (2022). https.\/\/www.leedsth.nhs.uk\/a-z-of-services\/pathology\/microbiology-2\/mycology\/mycology-samples\/antifungal-drug-monitor...."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/83020-voriconazole-induced-cholestatic-hepatotoxicity-in-an-immune-competent-patient","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:36:07Z","timestamp":1707507367000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/83020-voriconazole-induced-cholestatic-hepatotoxicity-in-an-immune-competent-patient"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,17]]},"references-count":14,"URL":"https:\/\/doi.org\/10.7759\/cureus.21346","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1,17]]}}}